<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04864561</url>
  </required_header>
  <id_info>
    <org_study_id>VLA2001-301</org_study_id>
    <nct_id>NCT04864561</nct_id>
  </id_info>
  <brief_title>Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine</brief_title>
  <acronym>COV-COMPARE</acronym>
  <official_title>A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (≥12 to &lt;18 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, randomized, observer-blind, active-controlled, superiority, study in&#xD;
      adults to compare the immunogenicity of VLA2001 to AZD1222 in terms of GMT of&#xD;
      SARS-CoV-2-specific neutralising antibodies. Furthermore, VLA2001 will be compared to placebo&#xD;
      in an adolescent population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 4000 Adult participants will be recruited in the study. About 3000 participants&#xD;
      aged 30 years and above will be randomized in a 2:1 ratio to receive 2 intramuscular&#xD;
      recommended doses of either VLA2001 (n=2000) or AZD1222 (n=1000). In addition, approximately&#xD;
      1000 subjects aged 18-29 years will participate in this study in a non-randomized, open-label&#xD;
      fashion to receive VLA2001. The 2 doses of vaccination for both vaccines will be administered&#xD;
      28 days apart, on Days 1 and 29. All visits will be conducted at the clinical site on an&#xD;
      outpatient basis.&#xD;
&#xD;
      Approximately 660 Adolescent participants will be recruited and randomized in a 1:1 ratio to&#xD;
      receive 2 intramuscular doses of either VLA2001 (n=330) or placebo (n=300). Adolescents&#xD;
      randomized to receive VLA2001, will receive a booster vaccination with VLA2001 at Day 208.&#xD;
      Participants in the placebo group will receive a 2-dose primary immunization with VLA2001 at&#xD;
      day 208 and the second vaccination 28 days later. For safety reasons, the first 16&#xD;
      adolescents will be enrolled in an open label, non-randomized manner (sentinel dosing).&#xD;
&#xD;
      Immunogenicity (neutralizing antibody titers) and safety will be assessed up to months 12&#xD;
      after the first vaccination.&#xD;
&#xD;
      Participants will be provided with an electronic Diary (e-Diary) and will be trained to&#xD;
      record specifically solicited systemic and local symptoms daily as well as any additional AEs&#xD;
      during follow-up period after each of both vaccinations up to the next visit to the site&#xD;
      until Day 43 visit has been completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">March 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>study participants aged 18-29 years at the time of enrolment are unblinded, study participant aged 12-18 and 30 years above at the time of enrolment are blinded (sentinel group is unblinded) until 28 days after vaccination on day 208, when all participants will be unblinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Immune response measured after completion of a 2-dose immunization schedule, as determined by the geometric mean titer (GMT) of SARS-CoV-2-specific neutralizing antibodies</measure>
    <time_frame>Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response measured after completion of a 2-dose immunization schedule, as determined by Seroconversion (definded as 4-fold increase from baseline) of SARS-CoV-2-specific neutralizing antibodies</measure>
    <time_frame>Day 43</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of any Adverse Events (AE)</measure>
    <time_frame>Up to Day 43 post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Seroconversion</measure>
    <time_frame>on Day 8 (age 55+ only), Day 29, Day 43, Day 71, Day 208 and Day 365.</time_frame>
    <description>Seroconversion is defined as &gt;= 4-fold increase in SARS-CoV-2 neutralizing antibody titer and S-protein binding IgG levels between Day 1 and post-vaccination timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response as determined by the geometric mean titer (GMT) of SARS-CoV-2-specific neutralizing antibodies.</measure>
    <time_frame>on Day 8 (age 55+ only), Day 29, Day 71, Day 208 and Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response as determined geometric mean titer (GMT) of IgG antibodies to SARS-CoV-2 S-protein</measure>
    <time_frame>on Day 8 (age 55+ only), Day 29, Day 43, Day 71, Day 208 and Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of T-cell responses (Th1/Th2 polarization) from PBMCs in a subset of participants after in vitro stimulation with SARS-CoV-2 antibodies using, e.g. ELISpot ir intracellular cytokine staining</measure>
    <time_frame>on Day 1, Day 8, Day 29, Day 43, Day 71, Day 208 and Day 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of solcited injection site and systemic reactions</measure>
    <time_frame>within 7 days after each and after any vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of any Adverse Events (AE)</measure>
    <time_frame>until Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of any unsolicited Adverse Events (AE)</measure>
    <time_frame>until Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of any unsolicited vaccine-related Adverse Events (AE)</measure>
    <time_frame>until Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of any Serious Adverse Event (SAE)</measure>
    <time_frame>until Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of any Adverse Event Of Special Interest (AESI)</measure>
    <time_frame>until Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">4679</enrollment>
  <condition>SARS-CoV-2 Virus Infection</condition>
  <arm_group>
    <arm_group_label>VLA2001</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&lt;30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1222</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&lt;30 years will receive VLA2001; participants aged ≥30 years will be randomised 2:1 to receive VLA2001 or AZD1222</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VLA2001 - adolescent part</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>≥12 to &lt; 18 years will be randomized 1:1 to receive VLA2001 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>≥12 to &lt; 18 years will be randomized 1:1 to receive VLA2001 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VLA2001</intervention_name>
    <description>whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide 2 vaccinations 28 days apart</description>
    <arm_group_label>VLA2001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AZD1222</intervention_name>
    <description>2 vaccinations 28 days apart AZD1222 is a recombinant, replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein.</description>
    <arm_group_label>AZD1222</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VLA2001 - adolescent part</intervention_name>
    <description>whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxid 2 vaccinations 28 days apart and with a booster vaccination on day 208. Placebo group will receive VLA2001 on day 208 and following second vaccination 28 days later.</description>
    <arm_group_label>VLA2001 - adolescent part</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 vaccinations 28 days apart with placebo (PBS buffer based on Dulbecco's PBS media formulation without Calcium and Magnesium )</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must have read, understood, and signed the informed consent form (ICF).&#xD;
&#xD;
          2. Participants of either gender aged 12 years and older at screening.&#xD;
&#xD;
          3. Medically stable&#xD;
&#xD;
          4. Must be able to attend all visits of the study and comply with all study procedures,&#xD;
&#xD;
          5. Women of childbearing potential (WOCBP) must be able and willing to use at least 1&#xD;
             highly effective method of contraception for a minimum of 3 months after the last dose&#xD;
             of study vaccine.&#xD;
&#xD;
          6. WOCBPs must have a negative pregnancy test prior to each vaccination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant is pregnant or planning to become pregnant within 3 months after study&#xD;
             vaccine administration.&#xD;
&#xD;
          2. History of allergy to any component of the vaccine.&#xD;
&#xD;
          3. Significant infection (e.g. positive SARS-CoV-2 RT-PCR) or other acute illness,&#xD;
             including fever &gt; 100 °F (&gt; 37.8 °C) 48 hours before vaccination.&#xD;
&#xD;
          4. Participant has a known or suspected defect of the immune system&#xD;
&#xD;
          5. Participant has a history of cerebral venous sinus thrombosis, heparin-induced&#xD;
             thrombocytopenia or antiphospholipid syndrome.&#xD;
&#xD;
          6. Participant has a history of malignancy in the past 5 years other than squamous cell&#xD;
             or basal cell skin cancer. If there has been surgical excision or treatment more than&#xD;
             5 years ago that is considered to have achieved a cure, the participant may be&#xD;
             enrolled. A history of hematologic malignancy is a permanent exclusion. Participants&#xD;
             with a history of skin cancer must not be vaccinated at the previous tumour site.&#xD;
&#xD;
          7. History of drug dependency or current use of drug of abuse or alcohol abuse at&#xD;
             screening.&#xD;
&#xD;
          8. Significant blood loss (&gt; 450 mL) or has donated 1 or more units of blood or plasma&#xD;
             within 6 weeks prior to the expected day of randomization (Visit 1).&#xD;
&#xD;
          9. History of clinically significant bleeding disorder, or prior history of significant&#xD;
             bleeding or bruising following IM injections or venepuncture.&#xD;
&#xD;
         10. Severe and uncontrolled ongoing autoimmune or inflammatory disease History of&#xD;
             Guillain-Barre syndrome or any other demyelinating condition.&#xD;
&#xD;
         11. Any other significant disease, disorder or finding which in the opinion of the&#xD;
             investigator may significantly increase the risk to the volunteer&#xD;
&#xD;
             Prior/concomitant therapy:&#xD;
&#xD;
         12. Receipt of immunoglobulin or another blood product within the 3 months before expected&#xD;
             day of randomization (visit 1) in this study or those who expect to receive&#xD;
             immunoglobulin or another blood product during this study.&#xD;
&#xD;
         13. Receipt of medications and or vaccinations intended to prevent COVID-19.&#xD;
&#xD;
         14. Receipt of any vaccine (licensed or investigational), other than licensed influenza&#xD;
             vaccine, within 28 days prior to the expected day of randomization (Visit 1).&#xD;
&#xD;
         15. Any member of the study team or sponsor.&#xD;
&#xD;
         16. An immediate family member or household member of the study's personnel.&#xD;
&#xD;
        Booster Vaccination (Adolescents)&#xD;
&#xD;
        In addition to the above described eligibility criteria, the following criteria must be&#xD;
        met:&#xD;
&#xD;
        - Participant has completed the primary vaccination schedule per protocol (i.e. has&#xD;
        received 2 study vaccinations within protocol windows).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valneva Clinical Development</last_name>
    <role>Study Chair</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valneva Clinical Development</last_name>
    <phone>+43 1 206 20</phone>
    <phone_ext>0</phone_ext>
    <email>office@valneva.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barnsley Hospital NHS FT</name>
      <address>
        <city>Barnsley</city>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blackpool Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Blackpool</city>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol and Weston NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cambridge Biomedical Research Centre</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cheadle Community Hospital</name>
      <address>
        <city>Cheadle</city>
        <zip>ST10 1NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western General Hospital, Edinburgh - NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH42XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Epsom and St. Helier University Hospitals NHS Trust</name>
      <address>
        <city>Epsom</city>
        <zip>KT187EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital-Glasgow- NHS Greater Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital NHS Foundation Trust</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <zip>LE39QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Foundation Trust Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E11BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panthera London</name>
      <address>
        <city>London</city>
        <zip>EN3 4GS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Free London NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital, Trust College HOspital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE59RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George's University Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NIHR UCLH Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital Newcastle</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northumbria Healthcare NHS Foundation Trust - North Tyneside General Hospital</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lakeside Healthcare Research</name>
      <address>
        <city>Northampton</city>
        <zip>NN17 2UR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Plymouth NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 5FP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panthera Biopartners Preston</name>
      <address>
        <city>Preston</city>
        <zip>PR1 6YA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panthera Biopartners Manchester</name>
      <address>
        <city>Rochdale</city>
        <zip>OL11 4AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern Care Alliance NHS Group, Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals NHS Trust</name>
      <address>
        <city>Truro</city>
        <zip>TR13LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2021</study_first_submitted>
  <study_first_submitted_qc>April 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VLA2001</keyword>
  <keyword>SARS-CoV-2 Virus Infection</keyword>
  <keyword>COVID-19</keyword>
  <keyword>inactivated-adjuvanted SARS-CoV-2 virus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

